Table 1.
Demographic and clinical description of patient participants
| Subject characteristics | C/C Subjects (n=8) | T Carriers (n=10) | Statistics | p |
|---|---|---|---|---|
| Demographics | ||||
| Age at fMRI | 38.9±4.3 | 42.9±4.1 | t=−0.67 | 0.52 |
| Sex | 5 Male/3 Female | 8 Male/2 Female | X2=0.68 | 0.41 |
| Race | 4 Caucasian/4 African-American | 9 Caucasian/1 African-American | X2=3.55 | 0.06 |
| Length of Illness (yrs) | 14.9±3.3 | 19.0±3.7 | t = 0.82 | 0.42 |
| Estimated Verbal IQ | 101 ±4 | 106±4 | t = −.072 | 0.48 |
| Edinburgh Handedness Inventory | 92±3 | 88±5 | t=0.62 | 0.55 |
| Clinical | ||||
| PANSS Positive | 13.3±2.1 | 15.4±1.9 | t=−.076 | 0.46 |
| PANSS Negative | 18.3±2.0 | 15.4±2.0 | t=1.00 | 0.33 |
| PANSS General | 28.0±2.0 | 28.9±1.3 | t=−.039 | 0.70 |
| PANSS Total | 59.5±4.2 | 59.7±4.3 | t=−.033 | 0.97 |
| CPZ Equivalents | 365±87 | 507±149 | t=−.077 | 0.45 |
| Performance and Motion | ||||
| Antisaccade Latency (ms) | ||||
| - correct trials | 295±15 | 345±28 | t=−1.58 | 0.14 |
| - error trials | 251 ±28 | 283±24 | t=−0.87 | 0.40 |
| Antisaccade % Error | 20.7±5.1 | 18.6±3.9 | t=0.33 | 0.75 |
| Error Self-correction % | 79.5 | 77.6 | t=0.19 | 0.85 |
| Total Motion (mm) | 1.71±0.26 | 1.62±0.19 | t=0.28 | 0.79 |
Values are reported as mean±standard error
fMRI, functional magnetic resonance imaging; PANSS, Positive and Negative Syndrome Scale; CPZ, chlorpromazine